NUVAXOVID™️ COVID-19 Vaccine (Recombinant protein, Adjuvanted) - Canada - European Medical Journal

NUVAXOVID™️ COVID-19 Vaccine (Recombinant protein, Adjuvanted) – Canada

Learn about the clinical efficacy and safety data for Nuvaxovid™️ COVID-19 Vaccine (Recombinant protein, Adjuvanted), a protein subunit vaccine authorized for use in Canada. The video can be viewed at your convenience.

This content is supported by Novavax, Inc.

 

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.